| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a protected amino acid, Boc-Asp-OH does not have a specific biological target. Its role is as a synthetic intermediate in the production of peptides and proteins. The final peptide products synthesized using Boc-Asp-OH may target various enzymes, receptors, or other proteins depending on their sequence and structure. Boc-Asp-OH itself is not known to bind to or modulate any biological target. It is classified as an aspartic acid derivative and is used exclusively for research purposes.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
Boc-Asp-OH does not exhibit intrinsic in vitro activity as it is not a pharmacologically active compound. Its use is limited to chemical synthesis. Amino acid derivatives like Boc-Asp-OH have been commercially used as ergogenic supplements, where they may influence the release of anabolic hormones and fuel availability. However, the specific in vitro activity of Boc-Asp-OH has not been characterized beyond its role as a building block. Any biological activity would be associated with the peptides synthesized from it. |
| ln Vivo |
In vivo activity is not applicable to Boc-Asp-OH as it is not a drug substance. The compound is intended for research use only and is not administered to animals for pharmacological evaluation. Its role is confined to the laboratory, where it serves as a key intermediate in the production of peptides that may subsequently undergo in vivo testing. The in vivo effects of Boc-Asp-OH itself have not been studied.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed with Boc-Asp-OH itself. However, the compound is used to synthesize peptides that can be evaluated in such assays. A typical protocol for assessing the binding of a peptide synthesized from Boc-Asp-OH to its target receptor would involve radioligand binding assays. In this assay, membrane preparations containing the receptor are incubated with increasing concentrations of the peptide and a fixed concentration of a radiolabeled ligand. The mixture is filtered, and radioactivity is measured to determine binding affinity.
|
| Cell Assay |
Cell-based assays are not performed with Boc-Asp-OH directly. The compound is used as a reagent for peptide synthesis. A typical cell-based assay would involve testing a peptide synthesized from Boc-Asp-OH. For example, a cell proliferation assay could be used to evaluate the effect of a peptide on cancer cell growth. Cells are seeded in 96-well plates, treated with the peptide for 24-72 hours, and cell viability is assessed using an assay such as MTT or CCK-8. This approach is standard for evaluating the bioactivity of peptide-based drug candidates.
|
| Animal Protocol |
In vivo animal experiments are not performed with Boc-Asp-OH itself. The compound is a research chemical used exclusively for peptide synthesis. If a peptide drug candidate synthesized from Boc-Asp-OH were to be evaluated in vivo, a typical protocol might involve administering the peptide to mice via a suitable route. For example, in a disease model, mice would be treated with the peptide, and relevant biomarkers or disease progression would be monitored to assess efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Boc-Asp-OH have not been characterized as it is not a drug candidate. The compound is intended for research use only. As a synthetic intermediate, its absorption, distribution, metabolism, and excretion (ADME) profile is not relevant to its intended use. The compound is typically stored as a powder at -20°C for up to 3 years or in solution at -80°C for up to 6 months to maintain stability.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Boc-Asp-OH has not been extensively studied. As a research chemical, it is not intended for human or veterinary use. Standard laboratory safety precautions should be followed when handling this compound. General toxicity data for amino acid derivatives suggest low acute toxicity, but specific toxicological information for Boc-Asp-OH is not available. Chronic toxicity, carcinogenicity, and reproductive toxicity studies have not been conducted.
|
| References | |
| Additional Infomation |
Nα-(tert-Butoxycarbonyl)-L-Aspartic acid is a derivative of aspartic acid.
Boc-Asp-OH is a protected amino acid derivative used as a key building block in peptide synthesis. It is not a drug and has no approved therapeutic indications or clinical trial history. The compound is commercially available from various chemical suppliers for research purposes only. Its primary application is in the pharmaceutical industry for the creation of specific therapeutic proteins and complex peptides. The Boc protecting group allows for selective deprotection, facilitating the synthesis of complex peptide sequences. |
| Molecular Formula |
C9H15NO6
|
|---|---|
| Molecular Weight |
233.22
|
| Exact Mass |
353.122
|
| CAS # |
13726-67-5
|
| PubChem CID |
99718
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
609.3±55.0 °C at 760 mmHg
|
| Melting Point |
116-118 °C(lit.)
|
| Flash Point |
322.3±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.550
|
| LogP |
2.05
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
16
|
| Complexity |
293
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(OC(N[C@H](C(O)=O)CC(O)=O)=O)C
|
| InChi Key |
KAJBMCZQVSQJDE-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C9H15NO6/c1-9(2,3)16-8(15)10-5(7(13)14)4-6(11)12/h5H,4H2,1-3H3,(H,10,15)(H,11,12)(H,13,14)/t5-/m0/s1
|
| Chemical Name |
(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2878 mL | 21.4390 mL | 42.8780 mL | |
| 5 mM | 0.8576 mL | 4.2878 mL | 8.5756 mL | |
| 10 mM | 0.4288 mL | 2.1439 mL | 4.2878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
